TIDMIMM
Immupharma PLC
11 April 2014
FOR IMMEDIATE RELEASE RNS REACH 11 APRIL 2014
ImmuPharma Sponsors the 2014 European Lupus Conference
Presentation Date: 24 April 2014
ImmuPharma PLC (LSE: IMM), ("ImmuPharma" or the "Company"), the
specialist drug discovery and development company, is pleased to
confirm that it is sponsoring the forthcoming European Lupus
Conference which takes place in Athens, Greece from April 23 - 26,
2014.
The "European Lupus Meetings" is a major forum for all people
interested in the disease: with approximately 800 physicians of
various disciplines (internal medicine, rheumatology, nephrology,
dermatology, obstetrics and gynecology, neurology), health
professionals, regulatory agencies, pharmaceutical industry and
patient representatives.
ImmuPharma recently had confirmation from Dr. Sylviane Muller,
Research Director at CNRS, Strasbourg, France and the key inventor
of Lupuzor, that she has been invited to present at the conference.
Her talk is planned in the Basic and Translational Symposium
(15-16.30pm CET) on Thursday April 24. The title of the session is
called "A novel way of immunomodulation in lupus". Her presentation
will focus partly on the on the highly competitive and efficacious
mode of mechanism of Lupuzor(TM) , ImmuPharma'spotential
blockbuster drug for Lupus, a chronic autoimmune disease.
Lupuzor(TM) has received Special Protocol Assessment and Fast Track
Designation from the FDA for a Phase III trial.
Also in attendance at the conference will be two of ImmuPharma's
eminent 'Scientific Advisory Board', Dr. Daniel J. Wallace,
Associate Director, Rheumatology Fellowship Program, Cedars-Sinai
Medical Center, Los Angeles, and a leading practitioner within the
field of Lupus, andProf. Cees GM Kallenberg, M.D., Ph.D. Prof.
Department of Rheumatology and Clinical Immunology, University
Medical Center Groningen who is a member of the 'European
Organisation Committee' for this forthcoming Lupus meeting. (Full
biographies can be found in 'Notes to Editors').
Details of the presentation given by Dr. Slyvianne Muller will
be provided by ImmuPharma following the conference.
For further information please contact:
ImmuPharma PLC (www.immupharma.com)
Dimitri Dimitriou, Chief Executive
Officer +44 20 7152 4080
Richard Warr, Chairman +44 20 7152 4080
Lisa Baderoon, Head of Investor
Relations +44 7721 413 496
+44 (0)20 7886
Panmure Gordon & Co 2500
Hugh Morgan, Fred Walsh
Notes to Editors
ImmuPharma
ImmuPharma is focusing on developing novel medicines with high
sales potential in specialist markets with serious unmet need.
ImmuPharma has five drug candidates in development, two platform
technologies and approximately 70 patents. The Company's most
advanced drug candidate, Lupuzor(TM) a potential blockbuster drug
for Lupus, a chronic autoimmune disease has received the approval
from the US FDA to enter phase III with a Special Protocol
Assessment and "Fast Track" designation. Most recent news confirmed
a five year GBP50m funding facility from Darwin Strategic and the
establishment of a Scientific Advisory Board to provide scientific
advice and support for Lupuzor's pivotal phase III programme.
ImmuPharma was founded and is led by a commercially focused Board
and management team with extensive experience.
www.immupharma.com
Dr. Sylviane Muller, Research Director at CNRS & Co-founder
of ImmuPharma France
Sylviane Muller is Professor at the Institute for Advanced Study
of the University of Strasbourg (USIAS), holder of the chair of
immunology and therapeutic chemistry, Distinguished class Research
Director and head of the 'Immunologie et chimie thérapeutiques'
unit of the "Centre National de la Recherche Scientifique" (CNRS),
the largest fundamental research organization in Europe. She
obtained her PhD at the University of Strasbourg. For two years,
she was a post-doctoral fellow in Freiburg (Germany) at the
Max-Planck Institute for Immunobiology. Her field of expertise
covers autoimmunity, immuno-peptides and synthetic vaccines. She
has made 23 patented discoveries and is widely published (330
publications and reviews/chapters). She was also a founder of
Neosystem, now Polypeptide-France, a leading peptide development
and manufacturing company. She is the key inventor of ImmuPharma's
Lupus lead drug candidate Lupuzor and has been working in this
field for more than ten years.
Dr. Daniel J Wallace, Associate Director, Rheumatology
Fellowship Program, Cedars-Sinai Medical Center, Los Angeles
Dr Wallace received his undergraduate and medical education at
the University of Southern California, graduating with an MD in
1974. His graduate medical training included an internship at Brown
University in Providence, Rhode Island, medical residency at
Cedars-Sinai Medical Center in Los Angeles and a fellowship in
rheumatology at UCLA. He is Board Certified in both Internal
Medicine and Rheumatology.
While a fellow at UCLA, he conducted pioneering arthritis
research that landed his picture in Time magazine and developed a
close relationship with his mentor, Edmund Dubois. Dr Dubois had
the largest lupus practice in the United States at the time and was
the principal editor of the only lupus textbook. He is the author
of 6 medical textbooks (including the last 4 editions of Dubois'
Lupus Erythematosus, All About Fibromyalgia, The Lupus Book, All
About Osteoarthritis, The New Sjogren's Syndrome Handbook, and
Fibromyalgia & Other Central Pain Syndromes), 19 book chapters,
and over 250 medical publications. The latter have appeared in the
New England Journal of Medicine, Annals of Internal Medicine, the
Lancet, Journal of Clinical Investigation, Journal of Immunology,
and Journal of the American Medical Association. Wallace's academic
efforts include having served as Chief of Rheumatology at
Cedars-Sinai Medical Center, Century City Hospital, and the City of
Hope Medical Center in Duarte, CA. He is currently a Clinical
Professor of Medicine at the David Geffen School of Medicine at
UCLA. His clinical practice is based at Cedars-Sinai, where he is
involved in the care of 2,000 lupus patients, the largest practice
of its kind in the United States. The Wallace Rheumatic Disease
Research Center currently runs over 30 clinical trials for patients
with rheumatoid arthritis, lupus, ankylosing spondylitis, psoriatic
arthritis and fibromyalgia.
The center has been the recipient of 3 National Institute of
Health grants. 20% of his time is spent in teaching and research,
providing free medical care.
Prof. Cees GM Kallenberg, M.D., Ph.D. (Netherlands) - Professor,
Department of Rheumatology and Clinical Immunology, University
Medical Center Groningen
Professor Cees GM Kallenberg received his medical training at
the Medical School of the University of Leiden, The Netherlands.
After getting his degree as an MD in 1972, he got additional
training in surgery and served as a military MD in the Dutch Army.
In 1975 he started his training as a resident in Internal Medicine
at the Groningen University Hospital and was registered as
internist in 1980. He worked as an internist and finished his PhD
studies on the subject 'Raynaud's phenomenon and Systemic
Autoimmune Disease' successfully in 1982. He further trained in
immunology and medical immunology and was registered as
immunologist and medical immunologist. He was appointed as
associate professor in Internal Medicine - Clinical Immunology in
1985 and as a full professor in 1993.
He has written more than 500 articles in international
peer-reviewed journals, gives lectures as an invited speaker on his
research topics on all major international meetings, and is an
editorial board member of several journals in clinical immunology,
nephrology and rheumatology.
About the Euopean Lupus Meeting : 2014
The 9th Eurolupus Meeting will be held in Athens Greece from
April 23rd to April 26th 2014. This is the premier European Lupus
Meeting with approximately 800 physicians of various disciplines
(internal medicine, rheumatology, nephrology, dermatology,
obstetrics and gynecology, neurology), nurses and patients.
The scientific program includes basic, translational and
clinical sessions as well as original research to be presented by
an international faculty of opinion leaders in lupus. In addition
to the main program, there will be a program for patients
coordinated by Lupus Europe, the European lupus patient
organization.
Attendees come to the meeting to be updated in the latest
developments, including the products, services and treatments
available in the marketplace. The meeting also includes satellite
symposia and other lupus-related educational and promotional
activities. www.lupus2014.org
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFSTSLIILIS
Immupharma (LSE:IMM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2023 to Apr 2024
